PFE · 10-Q · 2026Q3 · Full report

Capital Allocation Strategy

PFIZER INC · 2026-11-03 · Importance 26 · Surprise 24

Pfizer’s capital allocation framework prioritizes reinvestment in the business, maintaining and over the long term growing its dividend, and potentially resuming share repurchases after de-leveraging. The company expects leverage to remain around current levels or modestly higher through the next few years, citing anticipated unfavorable effects from patent-based or regulatory exclusivity expiries. Over the longer term, Pfizer expects to de-lever prudently while maintaining a balanced capital allocation strategy.

Key facts

• Pfizer expects leverage to remain around current levels, or modestly higher, through the transition period associated with anticipated unfavorable impacts from patent-based or regulatory exclusivity expiries over the next few years, and expects to de-lever over the longer term. source
• Pfizer's capital allocation framework prioritizes reinvesting in the business, maintaining and over the long term growing its dividend, and potentially resuming share repurchases after de-levering its balance sheet. source